In addition, immunosuppressants such as cyclosporine and cyclophosphamide, CD20 monoclonal antibodies and thrombopoietin receptor agonists have become new drugs in clinical treatment of ITP in recent years.[17] TPO is an important growth factor that regulates the proliferation and differentiation of megakaryocytes and mediates the production of platelets by megakaryocytes. This evidence concerns the gene MPL and autoimmune thrombocytopenic purpura.